Minimal/measurable residual disease refers to the small number of cancer cells remaining in the body after treatment.
How do we improve immunotherapy treatments to ensure long-lasting effectiveness, fewer side effects, and ensure they are accessible?
Dr Mitchell Smith, FLF CMO, explains Immunotherapy and what it means for people living with follicular lymphoma in terms of treatment.
Dr Mitchell Smith, FLF CMO, reports on the most exciting presentations at ASH 2023 including fundamental scientific discoveries and ongoing clinic trials.
We are thrilled to announce that this remarkable event saw us raise an astounding £500,000 to further our mission of finding a cure for follicular lymphoma.
The FLF will be attending the prestigious 65th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego this December.
The panel addressed the crucial topic of “Accelerating the Impact of the Cancer Mission Five-Fold” moderated by IQVIA Institutes Executive Director.
Our partnership with LLS continues with the second cycle of the “LLS-FLF United to CURE FL Awards”. This strategic alliance will further accelerate pioneering research and help cure follicular lymphoma.
The FLF joins forces with The Leukemia & Lymphoma Society to bring hope to those living with follicular lymphoma. The partnership marks a significant milestone in accelerating leading edge research.
This article presents key insights from the conference, shedding light on exciting developments in the field. The knowledge and insights we gained left us inspired and energised.
At the 17th International Conference on Malignant Lymphoma (17-ICML), the FLF hosted their own symposium: “What Will it Take to Cure FL?”. Read more to find out the key takeaways and highlights from the symposium.
In just the last six months, we have made tangible progress in advancing research, raising awareness, and working closely with patients.
Dr Mitchell Smith on Future Directions in FL Dr Mitchell Smith, CMO at the FLF, shares his insights in what the future holds for follicular
FLF shines a spotlight on Follicular Lymphoma at upcoming 17-ICML We are thrilled to announce that the Follicular Lymphoma Foundation (FLF) will be taking centre
On May 18th, the FLF hosted our very first webinar called “An Overview of Follicular Lymphoma: What You Need to Know.”
We’re thrilled to share a big step forward in our fight against follicular lymphoma. In April of this year, our founder, Nicola Mendelsohn, officially opened the new branch of the Follicular Lymphoma Foundation in Israel.
The Follicular Lymphoma Foundation (FLF) proudly hosted its first international FL Summit, titled “Joining Forces to Cure Follicular Lymphoma,” in Tel Aviv, Israel. The summit,
ASH Annual Meeting 2022 – summary and key take-outs By Dr Zoe Drymoussi During the 9-12th December 2022, the FLF team attended, in person, for
Looking back over the last 25 years for FL – the Rituximab era By Dr Mitchell Smith, Chief Medical Officer A recent re-publication marking 25
The FLF’s Precision Medicine Programme Research Goals Technical abstract: The FLF undertook extensive landscaping and scoping work, identifying a substantial set of unmet needs in
Research in focus: Bi-specific antibodies approval. By Dr. Zoe Drymoussi Over the last few years, a promising new class of treatments for advanced-stage FL has
FLF are attending the ASH 2022 Annual Meeting We are delighted that some of the team are able to attend the 64th ASH Annual Meeting
New funding of $2 million for research to get one step closer to a cure for Follicular Lymphoma. Our mission at the FLF is to
Kate Rogers joins from her previous role at GSK plc as Global Finance Transformation Lead at GSK. She also continues to serves as Non-Executive Director
Interesting summary of the impact and effectiveness of antibody responses to SARS- CoV-2 vaccines in patients with hematologic malignancies. A project from Michael J. Garil
For many people living with Follicular Lymphoma, periodic blood tests become a regular feature. There are several reasons you might need blood tests when affected
At the American Society for Hematology (ASH) Annual Meeting in December 2021, the most up-to-date research was shared on Follicular Lymphoma (FL), as well as
Any potential treatments for Follicular Lymphoma (and other forms of Non-Hodgkin lymphoma) must undergo extensive testing. They must be fully researched to confirm that they
The FLF places the patient at the heart of our organisation. This survey collated the unmet needs and prioritised our research goals.
Dr Mitchell Smith brings to the FLF over three decades of experience focused on blood cancers. The Follicular Lymphoma Foundation (FLF) has today announced the
